For the 25th year in a row, OhioHealth honored its long-term associates with a special day of shopping, recognition and celebration late this summer. It is one of the healthcare industry’s most unusual employee recognition programs.
“The Shopping Trip is not just a day of fun, food and shopping. It is a day of emotion, joy and celebration,” said Johnni Beckel, senior vice president and Chief Human Resources Officer. “When you see the honorees walking down the red carpet as hundreds of directors, vice presidents and presidents applaud their years of dedicated service to OhioHealth, it is really moving. They love it.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7073051-ohiohealth-shopping-trip-to-easton-for-long-term-associates/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the “ecosystem” of microbes populating the intestines—linked to the development of IBD.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7204351-crohn-s-colitis-foundation-of-america-gut-bacteria-new-strategies-to-prevent/
‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
LLNS, a leading healthcare communications company and part of Diversified Agency Services (DAS), is pleased to announce that Sharon Callahan, CEO of LLNS, has been recognized by the Women’s Venture Fund with its “Highest Leaf Award”. The award celebrates exceptional women who have demonstrated remarkable business leadership, developed a vision for business success and made outstanding contributions to their respective industries.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7234651-llns-sharon-callahan-business-leadership-women-s-venture-fund-healthcare
An expert group of specialists have come together to develop three new educational resources: the Journal of Perioperative Medicine, the Journal of Neonatal Intensive Care and an open-access online portal. These resources provide practical advice on key clinical issues, tackle controversial topics on which a consensus is needed, and highlight clinical concerns that need to be addressed in clinical practice. These resources are available through a new educational initiative called Cure&Care and are accessible at: www.cureandcareportal.com. Cure&Care officially launches at Euroanaesthesia 2014, in Stockholm, Sweden, 30 May – 3 June.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400535-cure-care-new-educational-initiative
Entering its 10th year of providing gout education, the Gout & Uric Acid Education Society (GUAES) is amplifying its efforts on May 22 – National Gout Awareness Day – and encouraging gout sufferers to seek immediate and ongoing treatment. Information and resources are available to both the general public and medical professionals through the organization’s new website, found at GoutEducation.org.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7134051-gout-and-uric-acid-education-society-national-gout-awareness-day
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
The Preeclampsia Foundation, the nation’s only non-profit patient advocacy organization for preeclampsia and related hypertensive disorders of pregnancy, today announced the results of a recent nationwide Preeclampsia Awareness Survey of more than 1,500 expectant and new mothers. These findings are driving the Foundation’s strategies associated with National Preeclampsia Awareness Month.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7171451-preeclampsia-foundation-awareness-survey-education-pregnancy-disorders
